Zobrazeno 1 - 10
of 127
pro vyhledávání: '"A. L. Oronsky"'
Autor:
Corey A. Carter, Bryan T. Oronsky, Scott Z. Caroen, Jan J. Scicinski, Aiste Degesys, Michelle M. Kim, Arnold L. Oronsky, Harry Lybeck, Pedro Cabrales, Neil Oronsky, Tony Reid, Joseph Roswarski, Christina Brzezniak
Publikováno v:
Case Reports in Oncology, Vol 9, Iss 1, Pp 171-176 (2016)
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT024899
Externí odkaz:
https://doaj.org/article/70d39e9ceae84df9a4472c901aa232f8
Autor:
Corey A. Carter, Aiste Degesys, Bryan Oronsky, Jan Scicinski, Scott Z. Caroen, Arnold L. Oronsky, Tony Reid, Pedro Cabrales, Joe Roswarski
Publikováno v:
Case Reports in Oncology, Vol 8, Iss 3, Pp 461-465 (2015)
Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms defined by the presence of cells with secretory granules and the potential to produce and release high levels of vasoactive peptides into the circulation, leading to severe flushing a
Externí odkaz:
https://doaj.org/article/cf5573c29ac74c178df671cde62ac1eb
Autor:
Xiaohui Wang, S. Scott Caroen, Bryan T. Oronsky, Xiaoning Guo, Tony R. Reid, David J. Sher, Michelle Lybeck, Lou Cannizzo, Bob Wardle, Nacer Abrouk, Arnold L. Oronsky, Pedro Cabrales
Publikováno v:
Journal of Medicinal Chemistry. 64:7261-7271
After extensive screening of aerospace compounds in an effort to source a novel anticancer agent, RRx-001, a first-in-class dinitroazetidine small molecule, was selected for advancement into preclinical and clinical development. RRx-001 is a minimall
Autor:
Corey A. Carter, Bryan T. Oronsky, Joseph Roswarski, Arnold L. Oronsky, Neil Oronsky, Jan Scicinski, Harry Lybeck, Michelle M. Kim, Michelle Lybeck, Tony R. Reid
Publikováno v:
OncoImmunology, Vol 6, Iss 10 (2017)
Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general, only a minorit
Externí odkaz:
https://doaj.org/article/47b37474a596420eb831402610b48908
Publikováno v:
Case Reports in Oncology, Vol 8, Iss 3, Pp 423-425 (2015)
Inhibition of vascular endothelial growth factor (VEGF) signaling, an initiator of tumor angiogenesis, inhibits tumor growth and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as an adjunct to standard chemotherapy like irinoteca
Externí odkaz:
https://doaj.org/article/485fa0c558b54843a9ce8b90121b19da
Publikováno v:
Seminars in Oncology
Seminars in oncology, vol 47, iss 5
Seminars in oncology, vol 47, iss 5
This article summarizes the likely attenuation properties of RRx-001 in COVID-19 based on its mechanism of action and the putative pathogenesis of the disease, which appears to activate inflammatory, oxidative, and immune cascades with the potential
Autor:
Bennett Thilagar, Bradley Brown, Arnold L. Oronsky, Tony R. Reid, Nacer Abrouk, Corey A. Carter, Erica Burbano, Angelique Coyle, Bryan Oronsky, Scott Caroen, Gina Varner, Curtis Scribner, Lindsey Ferry, Christopher A. Larson, Mary Flanagan Quinn
Publikováno v:
Future Oncology. 15:3427-3433
RRx-001 is a cysteine-directed anticancer alkylating agent with activity in a Phase II study in platinum refractory small cell lung cancer. Here, we describe the design of REPLATINUM, an open-label, Phase III trial. 120 patients with previously plati
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Frontiers in Oncology
Frontiers in Oncology
Glioblastoma is an aggressive and inevitably recurrent primary intra-axial brain tumor with a dismal prognosis. The current mainstay of treatment involves maximally safe surgical resection followed by radiotherapy over a 6-week period with concomitan
Autor:
Curtis Scribner, Tony R. Reid, Arnold L. Oronsky, Bryan Oronsky, Scott Caroen, Corey A. Carter
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epige
Autor:
Scott Caroen, Curtis Scribner, Pedro Cabrales, Arnold L. Oronsky, Bryan Oronsky, Xiaoning Guo, Tony R. Reid
Publikováno v:
Expert opinion on drug metabolismtoxicology. 17(4)
Introduction: The CD47 and SIRPα checkpoint pathway has garnered much interest within the anti-cancer research community, with multiple experimental checkpoint inhibitors targeting CD47 and SIRPα in development. The use of such checkpoint inhibitor